Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial

被引：12
|
作者：
Ryan, P. D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Neven, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Blackwell, K. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Dirix, L. Y. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Barrios, C. H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Miller, W. H., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fein, L. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fenton, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Benner, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Meech, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Paccagnella, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Sleight, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Yee, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Goss, P. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Ziekenhuis Leuven, Leuven, Belgium
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Sint Augustinus, Oncol Ctr, Antwerp, Belgium
[5] PUCRS Sch Med, Porto Alegre, RS, Brazil
[6] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[7] Ctr Oncol Rosario, Santa Fe, Argentina
[8] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[9] Pfizer Inc, Groton, CT 06340 USA
[10] Univ Minnesota, Minneapolis, MN USA
[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-17-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-17-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
    Lee, Soohyeon
    Im, Seock-Ah
    Kim, Gun Min
    Jung, Kyung Hae
    Kang, Seok Yun
    Park, In Hae
    Kim, Jee Hyun
    Lee, Kyoung Eun
    Ahn, Hee Kyung
    Lee, Moon Hee
    Kim, Hee-Jun
    Kim, Han Jo
    Lee, Jong In
    Koh, Su-Jin
    Park, Yeon Hee
    CANCERS, 2020, 12 (11) : 1 - 12
  • [42] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [43] Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.
    Mrozek, E.
    Schaaf, L. J.
    Ramaswamy, B.
    Shiels, D.
    Houton, L.
    Shapiro, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 387S - 387S
  • [44] The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'
    Atalay, G
    Dirix, L
    Biganzoli, L
    Beex, L
    Nooij, M
    Cameron, D
    Lohrisch, C
    Cufer, T
    Lobelle, JP
    Mattiaci, MR
    Piccart, M
    Paridaens, R
    ANNALS OF ONCOLOGY, 2004, 15 (02) : 211 - 217
  • [45] First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group
    Paridaens, R.
    Therasse, P.
    Dirix, L.
    Beex, L.
    Piccart, M. J.
    Cameron, D.
    Cufer, T.
    Roozendael, K.
    Nooy, M.
    Mattiacci, M. R.
    EJC SUPPLEMENTS, 2004, 2 (03): : 126 - 126
  • [46] Everolimus and exemestane in hormone receptor-positive advanced breast cancer: A comprehensive cancer center's experience.
    Moreira, Ines
    Ferreira, Marta
    Afonso, Ana
    Ferreira, Ana
    Rodrigues, Ana
    Vieira, Claudia
    Oliveira, Cristina
    Savva-Bordalo, Joana
    Dias, Joao
    Cassiano, Maria
    Abreu, Miguel
    Alves, Sara
    Sousa, Susana
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.
    Kahan, Zsuzsanna
    Petruzelka, Lubos
    Eniu, Alexandru
    Anghel, Rodica
    Koynov, Krassimir
    Vrbanec, Damir
    Lang, Istvan
    Ahlers, Silke
    Brodowicz, Thomas
    Zielinski, Christoph
    CANCER RESEARCH, 2013, 73 (08)
  • [48] Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 346 - 347
  • [49] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial (vol 11, pg, 82, 2011)
    Roberts, Nicholas
    CLINICAL BREAST CANCER, 2011, 11 (04) : 273 - 273
  • [50] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Sohita Dhillon
    Drugs, 2013, 73 : 475 - 485
12345